Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties

DOI: 10.1097/00005344-198703000-00009
Journal of Cardiovascular Pharmacology, 1987, 9, 317-27.

#	Paper	IF	Citations
98	Combined action drugs in the treatment of hypertension. *Drugs*, **1988**, 36 Suppl 6, 26-30	12.1	1
97	Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats. *Drugs*, **1988**, 36 Suppl 6, 31-6	12.1	8
96	Mode of Vasodilating Activity of Carvedilol in Isolated Perfused Hind Limbs of Rabbits. *Drugs*, **1988**, 36, 55-61	12.1	5
95	Pharmacological Profile of Vasodilating Action of Carvedilol in Isolated Canine Coronary Artery. *Drugs*, **1988**, 36, 62-63	12.1	1
94	Effects of Carvedilol on Plasma Hormonal and Biochemical Factors and Renal Function in Japanese Patients with Essential Hypertension. *Drugs*, **1988**, 36, 64-68	12.1	2
93	Dose-effect relationship of carvedilol in essential hypertension. An open study. *Drugs*, **1988**, 36 Suppl 6, 75-81	12.1	9
92	Pharmacokinetic and Pharmacodynamic Interactions of Combined Acute Administration of Carvedilol and Hydrochlorothiazide in Hypertensive Volunteers. *Drugs*, **1988**, 36, 113-117	12.1	5
91	Efficacy and Tolerance of Carvedilol in Combination with a Thiazide Diuretic in the Treatment of Essential Hypertension. *Drugs*, **1988**, 36, 118-123	12.1	3
90	Combination Therapy with Carvedilol and Nicardipine in Essential Hypertension. *Drugs*, **1988**, 36, 124-128	12.1	4
89	Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan. *Drugs*, **1988**, 36 Suppl 6, 129-35	12.1	12
88	Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics. *Drugs*, **1988**, 36 Suppl 6, 136-40	12.1	20
87	Renal Vasodilatory Action of Carvedilol in the Dog. *Drugs*, **1988**, 36, 155-159	12.1	5
86	Effects of Long Term Administration of Carvedilol on Renal Haemodynamics and Functions in DOCA Salt-Induced Accelerated Hypertension of Spontaneously Hypertensive Rats. *Drugs*, **1988**, 36, 165-168	12.1	3
85	Chapter 7. Antihypertensive Agents. *Annual Reports in Medicinal Chemistry*, **1988**, 23, 59-68	1.6	
84	Inhibitory action of carvedilol, a novel alpha, beta-adrenoceptor antagonist, on catecholamine secretion and calcium influx in cultured bovine adrenal chromaffin cells. *Biochemical Pharmacology*, **1989**, 38, 4461-5	6	7
83	Value of carvedilol in congestive heart failure secondary to coronary artery disease. *American Journal of Cardiology*, **1990**, 66, 1118-23	3	55
82	Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation. *European Journal of Clinical Pharmacology*, **1990**, 38 Suppl 2, S112-4	2.8	16

81	Influence of carvedilol and propranolol on coronary blood flow. *European Journal of Clinical Pharmacology*, **1990**, 38 Suppl 2, S122-4	2.8	7
80	Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial. *European Journal of Clinical Pharmacology*, **1990**, 38 Suppl 2, S158-63	2.8	8
79	Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of stereoselective presystemic metabolism. *Journal of Pharmaceutical Sciences*, **1990**, 79, 568-72	3.9	48
78	Identification of two major biliary metabolites of carvedilol in rats. *Xenobiotica*, **1990**, 20, 1025-34	2	12
77	Local cutaneous hemodynamic effects of carvedilol and labetalol in the anesthetized rat. *European Journal of Pharmacology*, **1990**, 176, 237-40	5.3	5
76	Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs. *British Journal of Pharmacology*, **1990**, 101, 686-90	8.6	7
75	Carvedilol increases the systemic bioavailability of oral digoxin. *British Journal of Clinical Pharmacology*, **1990**, 29, 486-90	3.8	33
74	Effect of Carvedilol on Venous Return: A Mechanism of Reduction in Blood Pressure. *The Japanese Journal of Pharmacology*, **1991**, 55, 186-189		
73	Effects of norepinephrine on the oxidative pentose phosphate pathway in the rat heart. *Circulation Research*, **1992**, 71, 451-9	15.7	17
72	Clinical pharmacology of carvedilol. *The Clinical Investigator*, **1992**, 70 Suppl 1, S27-36		6
71	Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure. *The Clinical Investigator*, **1992**, 70 Suppl 1, S53-7		5
70	Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischaemic heart disease? A comparison between intravenous and oral carvedilol. *The Clinical Investigator*, **1992**, 70 Suppl 1, S98-104		2
69	Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. *The Clinical Investigator*, **1992**, 70 Suppl 1, S105-13		24
68	Carvedilol: A Novel Cardiovascular Drug with Multiple Actions. *Cardiovascular Drug Reviews*, **1992**, 10, 127-157		55
67	Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. *Chirality*, **1992**, 4, 148-54	2.1	25
66	Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. *Cardiovascular Drugs and Therapy*, **1993**, 7, 193-206	3.9	15
65	Lack of a pharmacokinetic interaction between carvedilol and digitoxin or phenprocoumon. *European Journal of Clinical Pharmacology*, **1993**, 44, 583-6	2.8	4
64	Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. *Drugs*, **1993**, 45, 232-58	12.1	104

63	Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension. *American Journal of Hypertension*, **1994**, 7, 129-36	2.3	16
62	Carvedilol: A Novel Multiple Action Antihypertensive Drug that Provides Major Organ Protection. *Cardiovascular Drug Reviews*, **1994**, 12, 85-104		16
61	Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. *European Heart Journal*, **1995**, 16 Suppl F, 38-42	9.5	197
60	Cardiac adrenergic receptor effects of carvedilol. *European Heart Journal*, **1996**, 17 Suppl B, 8-16	9.5	116
59	Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. *European Heart Journal*, **1996**, 17 Suppl B, 24-9	9.5	68
58	Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. *Drugs*, **1997**, 54, 161-85	12.1	71
57	Comparison of the Effect of Carvedilol and Atenolol on Circadian Blood Pressure Profile in Patients with Essential Hypertension. *Clinical Drug Investigation*, **1997**, 14, 369-375	3.2	
56	Carvedilol in Comparison and in Combination with Isosorbide Dinitrate Sustained Release in Patients with Chronic Stable Effort-Induced Angina Pectoris. *Clinical Drug Investigation*, **1997**, 14, 465-473	3.2	3
55	Carvedilol versus verapamil in chronic stable angina: a multicentre trial. *European Journal of Clinical Pharmacology*, **1997**, 52, 95-100	2.8	30
54	Membrane potential of mesenteric artery from carvedilol-treated spontaneously hypertensive rats. *European Journal of Pharmacology*, **1998**, 344, 161-8	5.3	3
53	The Adrenergic Pharmacology of Carvedilol. *Heart Failure Reviews*, **1999**, 4, 21-28	5	6
52	Influence of beta-blockers on melatonin release. *European Journal of Clinical Pharmacology*, **1999**, 55, 111-5	2.8	153
51	Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. *American Journal of Cardiology*, **1999**, 83, 643-9	3	23
50	Ferulidilol: A vasodilatory and antioxidant adrenoceptor and calcium entry blocker, with ancillary β-agonist activity. *Drug Development Research*, **1999**, 47, 77-89	5.1	12
49	Clinical Pharmacology of Carvedilol. *Journal of Cardiovascular Pharmacology and Therapeutics*, **1999**, 4, 205-218	2.6	23
48	In vitro studies of the effects of beta-adrenergic drugs on retinal and posterior ciliary microarteries. *Survey of Ophthalmology*, **1999**, 43 Suppl 1, S183-90	6.1	15
47	Pharmacological effects of an aldehyde type alpha/beta-adrenoceptor blocking agent with vasodilating properties. *General Pharmacology*, **2000**, 34, 391-400		13
46	Usefulness of carvedilol in unstable angina pectoris. *American Journal of Cardiology*, **2000**, 85, 1173-8	3	5

45	Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. *American Journal of Veterinary Research*, **2000**, 61, 57-60	1.1	16
44	Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen. *Journal of Molecular and Cellular Cardiology*, **2000**, 32, 273-84	5.8	65
43	Effects of Carvedilol Therapy on Autonomic Function and Baroreflex Sensitivity in Individuals with Newly-Diagnosed Essential Hypertension. *Clinical Drug Investigation*, **2000**, 19, 63-70	3.2	
42	Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. *American Journal of Hypertension*, **2001**, 14, 27-31	2.3	158
41	Antiarrhythmic drug carvedilol inhibits HERG potassium channels. *Cardiovascular Research*, **2001**, 49, 361-70	9.9	79
40	Stereoselective effects of (R)- and (S)-carvedilol in humans. *Chirality*, **2001**, 13, 342-6	2.1	23
39	A new aspect of view in synthesizing new type beta-adrenoceptor blockers with ancillary antioxidant activities. *Bioorganic and Medicinal Chemistry*, **2001**, 9, 1739-46	3.4	14
38	Bloqueadores betaadren□gicos: an□sis comparativo. *FMC Formacion Medica Continuada En Atencion Primaria*, **2002**, 9, 605-612	0	
37	The Cardiovascular Society in the GDR (German Democratic Republic). *Clinical Research in Cardiology*, **2002**, 91 Suppl 4, 15-9		
36	Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). *American Journal of Cardiology*, **2003**, 92, 548-53	3	16
35	Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. *British Journal of Clinical Pharmacology*, **2003**, 55, 134-8	3.8	14
34	Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. *Journal of the American College of Cardiology*, **2003**, 41, 340-5	15.1	36
33	Cardioprotection by Carvedilol: antiapoptosis is independent of beta-adrenoceptor blockage in the rat heart. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2003**, 8, 207-15	2.6	33
32	Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cells. *International Heart Journal*, **2003**, 44, 963-78		16
31	Anti-hypertension effect of vanylidilol: a phenylaldehyde alpha/beta-adrenoceptor blocker with endothelium-dependent and K+ channels opening-associated vasorelaxant activities. *Pharmacology* , **2004**, 70, 140-51	2.3	6
30	Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol. *European Journal of Pharmacology*, **2004**, 491, 173-9	5.3	14
29	Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance. *Anti-Cancer Drugs*, **2004**, 15, 303-9	2.4	16
28	Hemodynamic effects of orally administered carvedilol in healthy conscious dogs. *American Journal of Veterinary Research*, **2005**, 66, 637-41	1.1	11

27	Gas chromatograph-mass spectrometric method for the determination of carvedilol and its metabolites in human urine. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2005**, 822, 70-7	3.2	27
26	Beta2-Adrenergic agonists suppress rat autoimmune myocarditis: potential role of beta2-adrenergic stimulants as new therapeutic agents for myocarditis. *Circulation*, **2006**, 114, 936-44	16.7	15
25	Carvedilol. *Cardiovascular Drug Reviews*, **2007**, 5, 135-153		
24	Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. *American Journal of Veterinary Research*, **2008**, 69, 1659-63	1.1	8
23	Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. *Journal of Cardiovascular Pharmacology*, **2008**, 51, 92-8	3.1	23
22	ESTIMATION OF CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC CARVEDILOLS IN PATIENTS WITH HYPERTENSION OF 1-2 GRADES. *Rational Pharmacotherapy in Cardiology*, **2008**, 4, 39-44	0.5	1
21	COMPARATIVE CONTROLLED STUDY OF ANTIHYPERTENSIVE EFFICACY AND SAFETY OF CARVEDILOL IN PATIENTS WITH HYPERTENSION AND OBESITY OR DIABETES 2 TYPE (BASED ON RESULTS OF MULTICENTER TRIAL ACCORD). *Rational Pharmacotherapy in Cardiology*, **2009**, 5, 19-24	0.5	1
20	Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol. *Journal of Pharmacological and Toxicological Methods*, **2009**, 59, 13-20	1.7	12
19	Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats. *Journal of Pharmacy and Pharmacology*, **2002**, 54, 821-5	4.8	5
18	Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction. *European Journal of Pharmacology*, **2010**, 640, 112-6	5.3	31
17	Cardioprotective and antiarrythmic activity of oxalate salt of 1-(isopropylamino)-3-(5-((isopropylamino) methyl)-2-methoxyphenoxy) propan-2-ol (PP-24): A newly synthesized aryloxypropanolamine derivative. *Biomedicine and Aging Pathology*, **2011**, 1, 84-89		1
16	Treatment of carvedilol for refractory hypertension in patients with renal diseases: A multicentre, prospective clinical trial. *Biomedicine and Aging Pathology*, **2011**, 1, 203-209		1
15	COMPARISON OF THE INFLUENCE OF LONG-TERM TREATMENT BASED ON CARVEDILOL OR BISOPROLOL ON METABOLIC PARAMETERS IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY RESULTS OF THE RANDOMIZED OPEN-LABEL PARALLEL-GROUPS STEPPED TRIAL CABRIOLET (PART I). *Rational Pharmacotherapy in Cardiology*, **2012**, 8, 488-499	0.5	
14	COMPARISON OF THE INFLUENCE OF LONG-TERM TREATMENT BASED ON CARVEDILOL OR BISOPROLOL ON METABOLIC PARAMETERS AND ERECTILE FUNCTION IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY RESULTS OF THE RANDOMIZED OPEN-LABEL PARALLEL-GROUPS STEPPED TRIAL CABRIOLET (PART 2). *Rational Pharmacotherapy in Cardiology*,	0.5	1
13	Click Synthesis of Some Novel O-Substituted Oximes Containing 1,2,3-Triazole-1,4-diyl Residues as New Analogs of Adrenoceptor Antagonists. *Helvetica Chimica Acta*, **2012**, 95, 491-501	2	16
12	Aortic elastic properties : effects of carvedilol versus nebivolol. *Herz*, **2013**, 38, 299-305	2.6	2
11	Formulation and evaluation of mucoadhesive buccal films impregnated with carvedilol nanosuspension: a potential approach for delivery of drugs having high first-pass metabolism. *Drug Delivery*, **2013**, 20, 224-35	7	49
10	Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats. *Drug Development and Industrial Pharmacy*, **2015**, 41, 1661-6	3.6	8

9	-Adrenergic Receptor Blockers Reduce the Occurrence of Keloids and Hypertrophic Scars after Cardiac Device Implantation: A Single-Institution Case-Control Study. *Plastic and Reconstructive Surgery*, **2017**, 139, 1248-1256	2.7	3
8	Use of beta-blockers and risk of serious upper gastrointestinal bleeding: a population-based case-control study. *Therapeutic Advances in Gastroenterology*, **2017**, 10, 919-929	4.7	0
7	Drugs Acting on Multiple Receptors: -Blockers with Additional Properties. *Handbook of Experimental Pharmacology*, **1990**, 131-226	3.2	4
6	Vasomolol: an ultra short-acting and vasorelaxant vanilloid type beta 1-adrenoceptor antagonist. *Journal of Cardiovascular Pharmacology*, **1996**, 28, 149-57	3.1	23
5	Ca2+ channel-blocking activity of propranolol and betaxolol in isolated bovine retinal microartery. *Journal of Cardiovascular Pharmacology*, **1998**, 32, 390-6	3.1	33
4	Eugenodilol: a third-generation beta-adrenoceptor blocker, derived from eugenol, with alpha-adrenoceptor blocking and beta2-adrenoceptor agonist-associated vasorelaxant activities. *Journal of Cardiovascular Pharmacology*, **1999**, 34, 10-20	3.1	19
3	Vanidipinedilol: a vanilloid-based beta-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities. *Journal of Cardiovascular Pharmacology*, **2000**, 35, 51-63	3.1	21
2	Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. *Circulation*, **1997**, 96, 183-91	16.7	103
1	Primenenie karvedilola u bol'nykh s metabolicheskim sindromom. *Systemic Hypertension*, **2005**, 2, 22-26	1.6	